However, DSS never began covering these drugs for weight loss
We can't stress this enough: consistency during this phase is paramount
Similar content being viewed by others Introduction In Italy, the use of innovative drugs for diabetes management has been steadily increasing, with a significant proportion of patients intensifying treatment regimen by adding oral medications more often than injectable ones
Research Insights Superior Weight Loss Outcomes In a 48-week phase 2 study, adults with obesity treated with retatrutide experienced mean weight reductions of 22.8% (8 mg dose) and 24.2% (12 mg dose), outperforming other weight loss medications
Historically, anti-obesity drugs have shown a lot of negative side effects and only moderate efficacy
(Source: AAOPM, April 2026) Where GLP-1s Sit on Formulary Tiers UnitedHealthcare, the largest commercial insurer in the United States, generally places GLP-1 receptor agonists on Tier 4 (specialty) or Tier 5 (non-preferred specialty) the tiers carrying the highest copay or coinsurance amounts
